Management of patients with persistent or recurrent Cushing's disease after initial pituitary surgery
- PMID: 32813595
- DOI: 10.1080/17446651.2020.1802243
Management of patients with persistent or recurrent Cushing's disease after initial pituitary surgery
Abstract
Introduction: Treatment options for persistent and recurrent Cushing's disease (CD) include an individualized approach for repeat surgery, medical treatment, radiation therapy (RT), and bilateral adrenalectomy (BLA).
Areas covered: In this expert opinion perspective, the authors review the latest treatment(s) for persistent/recurrent CD. A PubMed search was undertaken (English articles through May 2020) and relevant articles discussed. Repeat pituitary surgery should be considered in most patients with proven hypercortisolism; there is potential for cure with low risk of major complications. Medical therapy is valuable either alone, while awaiting the effects of RT, or in preparation for BLA. Medical therapy includes steroidogenesis inhibitors, agents that act at the pituitary or glucocorticoid receptor level, and novel agents in development. Radiation therapy has been used successfully to treat CD, but hypopituitarism risk and delayed efficacy (improved with radiosurgery) are major drawbacks. Laparoscopic BLA is safe and effective in patients with severe, difficult-to-manage hypercortisolism, but long-term follow-up is required as corticotroph tumor progression can develop.
Expert opinion: Treatment of persistent/recurrent CD is challenging. Most patients require >1 therapy to achieve long-lasting remission. There is currently no ideal single treatment option that provides high and rapid efficacy, low adverse effects, and preserves normal pituitary-adrenal axis function.
Keywords: Cushing’s disease; adrenalectomy; medical therapy; persistence; radiotherapy; recurrence; repeat surgery.
Similar articles
-
The role of bilateral adrenalectomy in the treatment of refractory Cushing's disease.Neurosurg Focus. 2015 Feb;38(2):E9. doi: 10.3171/2014.10.FOCUS14684. Neurosurg Focus. 2015. PMID: 25639327 Review.
-
Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy.Treat Endocrinol. 2002;1(2):79-94. doi: 10.2165/00024677-200201020-00002. Treat Endocrinol. 2002. PMID: 15765624 Review.
-
The Treatment of Cushing's Disease.Endocr Rev. 2015 Aug;36(4):385-486. doi: 10.1210/er.2013-1048. Epub 2015 Jun 11. Endocr Rev. 2015. PMID: 26067718 Free PMC article. Review.
-
Results of gamma knife surgery for Cushing's disease.J Neurosurg. 2013 Dec;119(6):1486-92. doi: 10.3171/2013.7.JNS13217. Epub 2013 Aug 9. J Neurosurg. 2013. PMID: 23930850
-
How to manage Cushing's disease after failed primary pituitary surgery.Eur J Endocrinol. 2024 Aug 30;191(3):R37-R54. doi: 10.1093/ejendo/lvae110. Eur J Endocrinol. 2024. PMID: 39276376 Review.
Cited by
-
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.Front Endocrinol (Lausanne). 2023 Oct 9;14:1165681. doi: 10.3389/fendo.2023.1165681. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37876540 Free PMC article. Clinical Trial.
-
New Trends in Treating Cushing's Disease.touchREV Endocrinol. 2024 Oct;20(2):10-15. doi: 10.17925/EE.2024.20.2.3. Epub 2024 Apr 8. touchREV Endocrinol. 2024. PMID: 39526050 Free PMC article.
-
Pituitary tumor centers of excellence for Cushing's disease.Pituitary. 2022 Oct;25(5):772-775. doi: 10.1007/s11102-022-01264-6. Epub 2022 Sep 10. Pituitary. 2022. PMID: 36087228 Free PMC article. No abstract available.
-
Cushing's syndrome is associated with altered adipokine profile.Front Endocrinol (Lausanne). 2022 Dec 6;13:1032329. doi: 10.3389/fendo.2022.1032329. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36561568 Free PMC article.
-
Consensus on diagnosis and management of Cushing's disease: a guideline update.Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources